10-94942290-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000771.4(CYP2C9):​c.430C>T​(p.Arg144Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.115 in 1,613,772 control chromosomes in the GnomAD database, including 11,971 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign,drug response,other (★★).

Frequency

Genomes: 𝑓 0.088 ( 755 hom., cov: 32)
Exomes 𝑓: 0.12 ( 11216 hom. )

Consequence

CYP2C9
NM_000771.4 missense

Scores

1
5
12

Clinical Significance

Likely benign; drug response; other criteria provided, multiple submitters, no conflicts B:1O:7

Conservation

PhyloP100: -0.0520

Publications

898 publications found
Variant links:
Genes affected
CYP2C9 (HGNC:2623): (cytochrome P450 family 2 subfamily C member 9) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.008835256).
BP6
Variant 10-94942290-C-T is Benign according to our data. Variant chr10-94942290-C-T is described in ClinVar as Likely_benign|drug_response|other. ClinVar VariationId is 8409.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.124 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CYP2C9NM_000771.4 linkc.430C>T p.Arg144Cys missense_variant Exon 3 of 9 ENST00000260682.8 NP_000762.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CYP2C9ENST00000260682.8 linkc.430C>T p.Arg144Cys missense_variant Exon 3 of 9 1 NM_000771.4 ENSP00000260682.6

Frequencies

GnomAD3 genomes
AF:
0.0882
AC:
13405
AN:
152046
Hom.:
755
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0236
Gnomad AMI
AF:
0.152
Gnomad AMR
AF:
0.0980
Gnomad ASJ
AF:
0.135
Gnomad EAS
AF:
0.000579
Gnomad SAS
AF:
0.0388
Gnomad FIN
AF:
0.118
Gnomad MID
AF:
0.136
Gnomad NFE
AF:
0.127
Gnomad OTH
AF:
0.112
GnomAD2 exomes
AF:
0.0920
AC:
23117
AN:
251228
AF XY:
0.0940
show subpopulations
Gnomad AFR exome
AF:
0.0223
Gnomad AMR exome
AF:
0.0680
Gnomad ASJ exome
AF:
0.136
Gnomad EAS exome
AF:
0.000436
Gnomad FIN exome
AF:
0.114
Gnomad NFE exome
AF:
0.128
Gnomad OTH exome
AF:
0.106
GnomAD4 exome
AF:
0.118
AC:
171842
AN:
1461608
Hom.:
11216
Cov.:
33
AF XY:
0.116
AC XY:
84405
AN XY:
727126
show subpopulations
African (AFR)
AF:
0.0195
AC:
652
AN:
33460
American (AMR)
AF:
0.0722
AC:
3227
AN:
44696
Ashkenazi Jewish (ASJ)
AF:
0.138
AC:
3599
AN:
26124
East Asian (EAS)
AF:
0.000227
AC:
9
AN:
39688
South Asian (SAS)
AF:
0.0490
AC:
4230
AN:
86254
European-Finnish (FIN)
AF:
0.113
AC:
6063
AN:
53420
Middle Eastern (MID)
AF:
0.120
AC:
693
AN:
5764
European-Non Finnish (NFE)
AF:
0.132
AC:
146976
AN:
1111836
Other (OTH)
AF:
0.106
AC:
6393
AN:
60366
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.453
Heterozygous variant carriers
0
9812
19625
29437
39250
49062
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
5244
10488
15732
20976
26220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0881
AC:
13400
AN:
152164
Hom.:
755
Cov.:
32
AF XY:
0.0870
AC XY:
6471
AN XY:
74388
show subpopulations
African (AFR)
AF:
0.0235
AC:
977
AN:
41536
American (AMR)
AF:
0.0978
AC:
1493
AN:
15266
Ashkenazi Jewish (ASJ)
AF:
0.135
AC:
470
AN:
3472
East Asian (EAS)
AF:
0.000387
AC:
2
AN:
5170
South Asian (SAS)
AF:
0.0388
AC:
187
AN:
4820
European-Finnish (FIN)
AF:
0.118
AC:
1249
AN:
10586
Middle Eastern (MID)
AF:
0.139
AC:
41
AN:
294
European-Non Finnish (NFE)
AF:
0.127
AC:
8609
AN:
67998
Other (OTH)
AF:
0.110
AC:
233
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
609
1218
1827
2436
3045
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
150
300
450
600
750
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.102
Hom.:
499
Bravo
AF:
0.0859
TwinsUK
AF:
0.136
AC:
503
ALSPAC
AF:
0.134
AC:
515
ESP6500AA
AF:
0.0268
AC:
118
ESP6500EA
AF:
0.131
AC:
1124
ExAC
AF:
0.0914
AC:
11093
Asia WGS
AF:
0.0160
AC:
57
AN:
3478
EpiCase
AF:
0.132
EpiControl
AF:
0.131

ClinVar

Significance: Likely benign; drug response; other
Submissions summary: Benign:1Other:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Warfarin response Other:2
Aug 09, 2018
OMIM
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:literature only

- -

-
Faculty of Pharmacy, Damascus University
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

rs1799853 is a SNP in the CYP2C9 gene and is linked to poor warfarin metabolism and risk of GI bleeding with warfarin, rs1799853 is associated with reduced enzyme activity and lower clearance rates of warfarin leading to higher rates of warfarin concentration likely responsive

not specified Benign:1
Mar 09, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Piroxicam response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals. Poor metabolizer

Lesinurad response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects. Poor metabolizer

Phenytoin response Other:1
Sep 24, 2020
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:case-control

May cause toxicity/ADR and poor metabolism/PK Decreased CYP2C9 function

not provided Other:1
Jul 09, 2015
Eurofins Ntd Llc (ga)
Significance:other
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles).

Flurbiprofen response Other:1
Feb 11, 2019
Medical Genetics Summaries
Significance:drug response
Review Status:criteria provided, single submitter
Collection Method:curation

The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance. Poor metabolizer

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.23
BayesDel_addAF
Benign
-0.39
T
BayesDel_noAF
Benign
-0.21
CADD
Benign
20
DANN
Uncertain
1.0
DEOGEN2
Benign
0.32
.;T
Eigen
Benign
-0.080
Eigen_PC
Benign
-0.31
FATHMM_MKL
Benign
0.039
N
LIST_S2
Benign
0.61
T;T
MetaRNN
Benign
0.0088
T;T
MetaSVM
Benign
-0.87
T
MutationAssessor
Uncertain
2.2
M;M
PhyloP100
-0.052
PrimateAI
Benign
0.35
T
PROVEAN
Pathogenic
-6.5
.;D
REVEL
Uncertain
0.34
Sift
Uncertain
0.028
.;D
Sift4G
Uncertain
0.019
.;D
Polyphen
1.0
.;D
Vest4
0.15
MPC
0.051
ClinPred
0.072
T
GERP RS
1.4
Varity_R
0.65
gMVP
0.20
Mutation Taster
=89/11
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1799853; hg19: chr10-96702047; COSMIC: COSV107290552; COSMIC: COSV107290552; API